Jiten Vora

5.8k total citations
148 papers, 4.2k citations indexed

About

Jiten Vora is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Jiten Vora has authored 148 papers receiving a total of 4.2k indexed citations (citations by other indexed papers that have themselves been cited), including 93 papers in Endocrinology, Diabetes and Metabolism, 26 papers in Molecular Biology and 23 papers in Surgery. Recurrent topics in Jiten Vora's work include Diabetes Treatment and Management (58 papers), Diabetes Management and Research (41 papers) and Metabolism, Diabetes, and Cancer (24 papers). Jiten Vora is often cited by papers focused on Diabetes Treatment and Management (58 papers), Diabetes Management and Research (41 papers) and Metabolism, Diabetes, and Cancer (24 papers). Jiten Vora collaborates with scholars based in United Kingdom, United States and Canada. Jiten Vora's co-authors include Simon Harding, Deborah Broadbent, Aftab Ahmad, William D. Fraser, David R. Owens, Naveed Younis, John R. Peters, Marc Evans, Michael J. Diver and Komal Imtiaz and has published in prestigious journals such as The Lancet, PLoS ONE and The Journal of Clinical Endocrinology & Metabolism.

In The Last Decade

Jiten Vora

144 papers receiving 4.0k citations

Peers

Countries citing papers authored by Jiten Vora

Since Specialization

Citations

This map shows the geographic impact of Jiten Vora's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jiten Vora with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jiten Vora more than expected).

Fields of papers citing papers by Jiten Vora

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jiten Vora. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jiten Vora. The network helps show where Jiten Vora may publish in the future.

Co-authorship network of co-authors of Jiten Vora

This figure shows the co-authorship network connecting the top 25 collaborators of Jiten Vora. A scholar is included among the top collaborators of Jiten Vora based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jiten Vora. Jiten Vora is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	First‐in‐human study of a pharmacological duodenal exclusion therapy shows reduced postprandial glucose and insulin and increased bile acid and gut hormone concentrations 2023 ·Diabetes Obesity and Metabolism ·Mark Fineman, (unknown), (unknown), (unknown), (unknown), Michael Horowitz, Jiten Vora, Christopher K. Rayner, Paul A. Wabnitz, Ashish Nimgaonkar	9
2	Factors associated with weight loss in people with overweight or obesity living with type 2 diabetes mellitus: Insights from the global DISCOVER study 2022 ·Diabetes Obesity and Metabolism ·Vittal Hejjaji, Juan José Gorgojo Martínez, Fengming Tang, (unknown), Andrew Cooper, Jesús Medina, (unknown), Kamlesh Khunti, Antonio Nicolucci, М. В. Шестакова, Linong Ji, Marília Brito Gomes, Hirotaka Watada, Jiten Vora, Ali O. Malik, Mikhail Kosiborod, Suzanne V. Arnold	2
3	Cardiovascular and renal safety of metformin in patients with diabetes and moderate or severe chronic kidney disease: Observations from the EXSCEL and SAVOR‐TIMI 53 cardiovascular outcomes trials 2021 ·Diabetes Obesity and Metabolism ·Lindsay E. Clegg, Yankang Jing, Robert C. Penland, David W. Boulton, Adrian F. Hernandez, Rury R. Holman, Jiten Vora	5
4	Safety and cost-effectiveness of individualised screening for diabetic retinopathy: the ISDR open-label, equivalence RCT 2020 ·Diabetologia ·(unknown), Deborah Broadbent, (unknown), Christopher P. Cheyne, Marilyn James, (unknown), Irene Stratton, (unknown), Tracy Moitt, Jiten Vora, Mark Gabbay, Marta García‐Fiñana, Simon Harding	22
5	A systematic review of the safety of incretin-based therapies in type 2 diabetes 2016 ·Expert Review of Endocrinology & Metabolism ·Marc Evans, Stephen C. Bain, Jiten Vora	8
6	Results from the UK cohort of SOLVE: Providing insights into the timing of insulin initiation in people with poorly controlled type 2 diabetes in routine clinical practice 2014 ·Primary care diabetes ·Kamlesh Khunti, Jiten Vora, Melanie J. Davies	12
7	Fuzzy Expert System for Type 2 Diabetes Mellitus (T2DM) Management Using Dual Inference Mechanism 2013 ·Edge Hill University Research Information Repository (Edge Hill University) ·Nonso Nnamoko, (unknown), David England, Jiten Vora	5
8	A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations 2011 ·Diabetes Obesity and Metabolism ·Marc Evans, P.‐M. Schumm‐Draeger, Jiten Vora, Allen B. King	109
9	Mechanisms of glucose intolerance in cystic fibrosis 2009 ·Diabetic Medicine ·(unknown), H. Miller, Paul W. Dyce, R. Grainger, Rachael A. Hughes, Jiten Vora, M.J. Ledson, Martin Walshaw	48
10	Testosterone replacement-induced hyperprolactinaemia: case report and review of the literature 2005 ·Annals of Clinical Biochemistry International Journal of Laboratory Medicine ·Ravinder Sodi, (unknown), M J Diver, L. Ranganath, Jiten Vora	16
11	Effects of Losartan-based therapy on the incidence of end-stage renal disease and associated costs in type 2 diabetes mellitus: A retrospective cost-effectiveness analysis in the United Kingdom 2005 ·Current Therapeutic Research ·Jiten Vora, George W. Carides, Paul Robinson	6
12	Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study 2003 ·The Lancet ·Naveed Younis, Deborah Broadbent, Jiten Vora, Simon Harding	213
13	Painful cutaneous lesions, renal failure and urgent parathyroidectomy. 2002 ·PubMed ·Naveed Younis, Robert A. Sells, A. D. DESMOND, Timothy R. Helliwell, (unknown), Mahdi Jibani, Jiten Vora	13
14	131I-MIBG radionuclide therapy is safe and cost-effective in the control of symptoms of the carcinoid syndrome 2001 ·European Journal of Surgical Oncology ·(unknown), Sobhan Vinjamuri, Clare Byrne, Paula Ghaneh, Jiten Vora, Graeme J. Poston	43
15	Radioactive labelled insulin kinetics 1995 ·International Journal of Mathematical Education in Science and Technology ·A. G. Shannon, (unknown), Jiten Vora, D. R. Owens	2
16	Impact of initial treatment on renal function in newly-diagnosed Type 2 (non-insulin-dependent) diabetes mellitus 1993 ·Diabetologia ·Jiten Vora, J. Dolben, J D Williams, John R. Peters, D. R. Owens	31
17	Renal hemodynamics in newly presenting non-insulin dependent diabetes mellitus 1992 ·Kidney International ·Jiten Vora, J. Dolben, John Dean, David M. Thomas, (unknown), David R. Owens, John R. Peters	113
18	Simultaneous determination of glomerular filtration rate and effective renal plasma flow 1991 ·Clinical Physics and Physiological Measurement ·Jiten Vora, (unknown), David R. Owens, John R. Peters	11
19	Recombinant DNA derived monomeric insulin analogue: comparison with soluble human insulin in normal subjects. 1988 ·BMJ ·Jiten Vora, David R. Owens, J. Dolben, (unknown), (unknown), Seungha Kang, (unknown), Jens Brange	29
20	Possible new method to improve detection of diabetic retinopathy: Polaroid non-mydriatic retinal photography. 1985 ·BMJ ·Robert E. J. Ryder, Jiten Vora, (unknown), David R. Owens, T M Hayes, (unknown)	49

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact